SuperworthCoherus Oncology shares outstanding CHRS
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Jun 30, 2026
- 154.8M
- On a year earlier
- +33.4%
- more shares
Coherus Oncology had 154.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 33.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 120.4M | +4% |
| FY2024 | 115.4M | +3% |
| FY2023 | 111.6M | +43% |
| FY2022 | 78M | +1% |
| FY2021 | 76.8M | −13% |
| FY2020 | 87.8M | +18% |
| FY2019 | 74.1M | −2% |
| FY2018 | 75.8M | +30% |
| FY2017 | 58.3M | +32% |
| FY2016 | 44.3M | +14% |
| FY2015 | 38.9M | +96% |
| FY2014 | 19.8M | +404% |
| FY2013 | 3.9M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 154.8M | +33% | |
| Q1 FY26 | 136.4M | +18% | |
| Q4 FY25 | 120.4M | +4% | |
| Q3 FY25 | 116.2M | +1% | |
| Q2 FY25 | 116.1M | +1% | |
| Q1 FY25 | 115.9M | +3% | |
| Q4 FY24 | 115.4M | +3% | |
| Q3 FY24 | 115.2M | +18% | |
| Q2 FY24 | 114.8M | +32% | |
| Q1 FY24 | 112.7M | +42% | |
| Q4 FY23 | 111.6M | +43% | |
| Q3 FY23 | 97.7M | +26% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Coherus Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.